Prescription drug · ANDA
Fenofibrate NDC 60505-3120
Fenofibrate 43 mg/1 · Capsule · Oral · Apotex Corp.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 60505-3120-1 | 60505312001 | 100 CAPSULE in 1 BOTTLE (60505-3120-1)Marketed from Jul 26, 2013 | |
| 60505-3120-3 | 60505312003 | 30 CAPSULE in 1 BOTTLE (60505-3120-3)Marketed from Jul 26, 2013 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Fenofibrate
- Generic name (nonproprietary)
- fenofibrate
- Active ingredients
- Fenofibrate — 43 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Apotex Corp.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 202252
- Marketing start
- Listing expires
- Identifiers
- Product ID 60505-3120_81d94e71-5260-d81d-f3b9-070ec3c0743aSPL ID 81d94e71-5260-d81d-f3b9-070ec3c0743aSPL set ID 68024459-987a-9cf4-f539-4959093bc9f0RxCUI 483425, 483427UNII U202363UOSUPC 0360505312139, 0360505312030
- Pharmacologic class
- Peroxisome Proliferator Receptor alpha Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N460505312001followed by a unit qualifier and the quantityPackage 60505-3120-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Fenofibrate capsules, USP are indicated as adjunctive therapy to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. Limitations of Use Markedly elevated levels of serum TG (e.g., >2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined [see Warnings and Precautions (5.7)] . Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized …
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 202252
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Fenofibrate | Fenofibrate 130 mg/1 | CapsuleOral | Apotex Corp. | 60505-3121 |